Treatment of high-risk neuroblastoma
Although high-dose chemotherapy and autologous stem cell transplantation (HDCT/autoSCT) have improved the prognosis for patients with high-risk neuroblastoma (NB), event-free survival rates remain in the range of 30 to 40%, which is unsatisfactory. To further improve outcomes, several clinical trial...
Saved in:
Main Author: | Ki Woong Sung (Author) |
---|---|
Format: | Book |
Published: |
Korean Pediatric Society,
2012-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Treatment of High-Risk Neuroblastoma
by: Julie Krystal, et al.
Published: (2023) -
High-Risk Neuroblastoma Treatment Review
by: Valeria Smith, et al.
Published: (2018) -
Long-term effects of local radiotherapy on growth and vertebral features in children with high-risk neuroblastoma
by: Kyungmi Yang, et al.
Published: (2024) -
Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma
by: Eunjin Lee, et al.
Published: (2020) -
Excellent treatment outcomes in children younger than 18 months with stage 4 nonamplified neuroblastoma
by: Chiwoo Kim, et al.
Published: (2018)